RS66167B1 - Ebselen za upotrebu u lečenju menierove bolesti - Google Patents

Ebselen za upotrebu u lečenju menierove bolesti

Info

Publication number
RS66167B1
RS66167B1 RS20241265A RSP20241265A RS66167B1 RS 66167 B1 RS66167 B1 RS 66167B1 RS 20241265 A RS20241265 A RS 20241265A RS P20241265 A RSP20241265 A RS P20241265A RS 66167 B1 RS66167 B1 RS 66167B1
Authority
RS
Serbia
Prior art keywords
composition
ebselen
use according
compounds
treatment
Prior art date
Application number
RS20241265A
Other languages
English (en)
Serbian (sr)
Inventor
Jonathan Kil
Original Assignee
Sound Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sound Pharmaceuticals Incorporated filed Critical Sound Pharmaceuticals Incorporated
Publication of RS66167B1 publication Critical patent/RS66167B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RS20241265A 2016-05-18 2017-05-18 Ebselen za upotrebu u lečenju menierove bolesti RS66167B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662338443P 2016-05-18 2016-05-18
EP17800188.9A EP3458045B1 (en) 2016-05-18 2017-05-18 Ebselen for use in the treatment of meniere's disease
PCT/US2017/033379 WO2017201318A1 (en) 2016-05-18 2017-05-18 Treatment of meniere's disease

Publications (1)

Publication Number Publication Date
RS66167B1 true RS66167B1 (sr) 2024-12-31

Family

ID=60326098

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20241265A RS66167B1 (sr) 2016-05-18 2017-05-18 Ebselen za upotrebu u lečenju menierove bolesti

Country Status (20)

Country Link
US (1) US12427138B2 (https=)
EP (2) EP4461360A3 (https=)
JP (1) JP7100866B2 (https=)
KR (1) KR102474830B1 (https=)
CN (1) CN109475518A (https=)
AU (1) AU2017267732B2 (https=)
CA (1) CA3026007A1 (https=)
CY (1) CY1127309T1 (https=)
DK (1) DK3458045T3 (https=)
ES (1) ES2990157T3 (https=)
FI (1) FI3458045T3 (https=)
HR (1) HRP20241559T1 (https=)
HU (1) HUE069280T2 (https=)
LT (1) LT3458045T (https=)
PL (1) PL3458045T3 (https=)
PT (1) PT3458045T (https=)
RS (1) RS66167B1 (https=)
SI (1) SI3458045T1 (https=)
SM (1) SMT202400469T1 (https=)
WO (1) WO2017201318A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115135321B (zh) 2020-02-24 2023-12-05 上海科技大学 N-取代吡啶基苯并异硒唑酮化合物的应用
JP2025504263A (ja) * 2021-12-23 2025-02-10 ユニバーシティ オブ ロチェスター 内耳への薬剤の送達のためのｃｓｆ輸送経路
EP4536191A1 (en) 2022-06-06 2025-04-16 Sound Pharmaceuticals Incorporated Ebselen containing oral dosage forms
US20250352482A1 (en) 2022-06-06 2025-11-20 Sound Pharmaceuticals Inc. Amorphous dosage form containing ebselen
WO2026073143A1 (en) * 2024-09-27 2026-04-02 Sound Pharmaceuticals Inc. Cochlear implant eluting ebselen for treating hearing loss

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3827093A1 (de) 1988-08-10 1990-02-15 Nattermann A & Cie Verfahren zur herstellung von hochreinem ebselen
JPH02202818A (ja) 1988-12-09 1990-08-10 Allergan Inc 白内障の治療における２―置換―チアゾリジン―４―カルボン酸類の用途
ES2497716T3 (es) * 2002-01-04 2014-09-23 Sound Pharmaceuticals Incorporated Composiciones para utilizar en métodos destinados a tratar la pérdida auditiva
US20070105782A1 (en) * 2005-10-07 2007-05-10 Board Of Trustees Of Southern Illinois University Protectant Combinations for Reducing Toxicities
AU2007277193B2 (en) * 2006-07-25 2013-06-13 Hough Ear Institute Methods for treating acute acoustic trauma
CA2723621A1 (en) 2008-05-15 2009-11-19 Edison Pharmaceuticals, Inc Treatment of hearing and balance impairments using compounds having erythropoietin activity
JP6013736B2 (ja) 2008-12-22 2016-10-25 オトノミ—，インク． 耳の障害の処置のための耳感覚細胞モジュレータ組成物の制御放出及びその方法
ES2893825T3 (es) 2011-02-04 2022-02-10 Hough Ear Inst Métodos de tratamiento de lesiones cerebrales
EP2736890A4 (en) 2011-07-28 2015-07-15 Promentis Pharm Inc Cysteine PRODRUGS
CN102526734A (zh) * 2012-01-12 2012-07-04 王玉丰 治疗年龄相关性听力损失的药物组合物及其应用
US20150374779A1 (en) 2014-06-26 2015-12-31 Auris Medical Ag Pharmacologic treatments of meniére's disease
KR20230107890A (ko) * 2014-09-15 2023-07-18 사운드 파마슈티칼스 인코퍼레이티드 정신병적 장애를 치료하기 위한 방법 및 조성물
JP7033789B2 (ja) * 2016-06-29 2022-03-11 オトノミー，インク． トリグリセリド耳用製剤とその使用
US10750005B2 (en) 2018-09-27 2020-08-18 International Business Machines Corporation Selective email narration system

Also Published As

Publication number Publication date
ES2990157T3 (es) 2024-11-29
EP4461360A3 (en) 2025-01-22
LT3458045T (lt) 2024-12-10
AU2017267732B2 (en) 2023-04-13
HRP20241559T1 (hr) 2025-02-14
CY1127309T1 (el) 2026-02-25
JP2019516727A (ja) 2019-06-20
HUE069280T2 (hu) 2025-02-28
KR102474830B1 (ko) 2022-12-06
US20200261417A1 (en) 2020-08-20
EP3458045A4 (en) 2020-09-16
EP3458045A1 (en) 2019-03-27
US12427138B2 (en) 2025-09-30
CA3026007A1 (en) 2017-11-23
SI3458045T1 (sl) 2025-03-31
KR20190043499A (ko) 2019-04-26
EP4461360A2 (en) 2024-11-13
AU2017267732A1 (en) 2018-12-20
PT3458045T (pt) 2024-10-28
FI3458045T3 (fi) 2024-10-24
SMT202400469T1 (it) 2025-01-14
JP7100866B2 (ja) 2022-07-14
EP3458045B1 (en) 2024-08-21
WO2017201318A1 (en) 2017-11-23
CN109475518A (zh) 2019-03-15
DK3458045T3 (da) 2024-11-04
PL3458045T3 (pl) 2025-01-07

Similar Documents

Publication Publication Date Title
US20220152055A1 (en) Methods and compositions for treating various disorders
RS66167B1 (sr) Ebselen za upotrebu u lečenju menierove bolesti
JP2023169413A (ja) 精神病性障害を治療するための方法および組成物
US20160022632A1 (en) Combination of canagliflozin and probenecid for the treament of hyperuricemia
EP0730865B1 (en) Use of serotonin and dopamine receptor blockers for the treatment of mental disorders associated with cerebrovascular disease
KR20150119227A (ko) 라퀴니모드에 의한 다발성 경화증의 진행형 형태의 치료
TW202228708A (zh) 樟芝酸ｈ與其衍生物用於治療神經系統疾病的用途
US20120157475A1 (en) Combination Preparation Against Vertigo
JP7656608B2 (ja) トラピジルを使用した認知障害の治療
WO2022246200A1 (en) Methods of treating kidney diseases or disorders
JP6068447B2 (ja) 過活動膀胱の治療のためのソリフェナシンと唾液分泌刺激剤の組合せ
HUT50440A (en) Process for producing pharmaceutical compositions for treating schizophrenia
JP2020530472A (ja) シュニッツラー症候群の治療方法
JP2024518426A (ja) 投与レジメン
WO1998008504A1 (en) Remedies for allergic dermatitis
TW202122086A (zh) 嗜中性白血球彈性蛋白酶抑制劑在肺部疾病中之使用
JP2022538569A (ja) 睡眠障害を伴うｃｎｓ障害の治療
US20250288518A1 (en) Methods of using radiprodil in the treatment of disorders
WO2025228863A1 (en) Dose regimen for a 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivative
TW202448432A (zh) 肌萎縮性側索硬化症（ａｌｓ）的治療
WO2025184490A1 (en) N-[4-fluor-5-[[(2s, 4 r)-4-[(6-methoxy-4-pyrimidinyl)oxy]- 2-methyl-1-pyrrolidinyl] methyl ]-2-thiazolyl]acetamid for use in the treatment of alzheimer disease
JP2023529311A (ja) Ｃｆｔｒ関連疾患および障害を治療する方法
JP2008501785A (ja) 子宮腫瘍の治療用医薬の調製のための７−ｔ−ブトキシイミノメチルカンプトテシンの使用
CN112745279A (zh) 醋甲唑胺及其类似物及其在正常压力脑积水的治疗中的应用
HK1170420A (en) Therapeutically effective amounts of r(+) and s(-) pramipexole for use in the treatment of parkinson's disease